MoonLake Immunotherapeutics(MLTX) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

MLTX MoonLake Immunotherapeutics

Watchlist

37.125
+0.375+1.02%

Trading Mar 11 09:51 ET

2.35BMarket Cap-19.64P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
Moomoo NewsFeb 28 06:34 ET · Ratings
Goldman Sachs Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $73
Moomoo NewsFeb 27 10:32 ET · Ratings
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $66 to $100
Moomoo NewsFeb 27 08:00 ET · Ratings
MoonLake Immunotherap Is Maintained at Buy by Needham
Dow JonesFeb 27 04:58 ET · Ratings
Needham Maintains Buy on MoonLake, Raises Price Target to $66
BenzingaFeb 27 04:47 ET · Ratings
MoonLake Analyst Ratings
BenzingaFeb 27 04:46 ET · Ratings

Comments

Movers and Shakers

Jan 17 08:01

Columns Today's Pre-Market Movers and Top Ratings | QRVO, MLTX, NET and More

Morning Movers
Gapping up
$Qorvo (QRVO.US)$ saw a 7% increase after reports of activist investor Starboard Value acquiring a 7.7% stake.
$MoonLake Immunotherapeutics (MLTX.US)$ gained over 4% following Goldman Sachs' upgrade to 'buy', citing positive expectations for its phase 3 trial data.
$Life360 (LIF.US)$ rose 3% following UBS's upgrade to 'buy', based on promising ad revenue potential.
$Rivian Automotive (RIVN.US)$ increased 2...

Meltyy

Jan 24, 2024 03:25

Ph2 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...

Meltyy

Jan 3, 2024 06:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2...

Moomoo AI

Oct 16, 2023 06:34

MoonLake's CEO expresses confidence in 120mg being the optimal dose and highlights the drug's improved durability of response compared to Humira in other studies.